Product Description
Anagliptin is an orally available, potent, selective inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Anagliptin)
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Sanwa Kagaku Kenkyusho
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Coronary Artery Disease|Type 2 Diabetes
Phase 3: Type 2 Diabetes
Phase 1: Kidney Diseases|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SSUG | N/A |
Unknown status |
Type 2 Diabetes |
2021-03-30 |
|
| ACACIA | P4 |
Completed |
Type 2 Diabetes |
2020-09-02 |
|
| REASON | P4 |
Completed |
Coronary Artery Disease |
2018-01-01 |
|
| JapicCTI-132246 | P3 |
Completed |
Type 2 Diabetes |
2015-09-01 |